Committed to the Future of Antibiotics

11 April 2017

Da Volterra Anticipating an Invigorating ECCMID 2017

ECCMID 2017 in Vienna, Austria is rapidly approaching the (...)

8 March 2017

Da Volterra's CSO will present a webinar: Antibiotics & the Microbiome March 9th

Our CSO, Jean de Gunzburg will present a free webinar in (...)

6 March 2017

Da Volterra Attending BioSpring 2017 in Barcelona

Da Volterra will be attending BioSpring in Barcelona March (...)

9 January - 12 January 2017

Da Volterra Looking Forward to Attending JMP in January

Da Volterra will be represented at JP Morgan January 9-12 in (...)

Who we are

Da Volterra:
Committed to the Future of Antibiotics

Da Volterra is a biotechnology company developing a portfolio of unique products in the antibacterial field, with a specific focus on antibiotic resistance.

Our most advanced product is DAV132, developed to prevent the disruption of the intestinal microbiota and prevent Clostridium difficile infections associated with antibiotic use. Discover DAV132 in the video below:

DAV132 has already undergone three phase I clinical trials. It has been developed using in-house expertise on resistant gut microbiomes and proprietary drug delivery technologies. Learn more >

500,000 Americans infected
by Clostridium difficile
each year

Learn more >


Developpeur PHP Drupal